Top 10 Life Science VC Funds in Australia
A list of 10 VC funds that invest in Life science startups based in Australia. We rank investors based on the number of investments they made in Life science companies from Australia. We update this investor list every month.Top 10 Life Science VC Funds in Australia
Investor | Life Science Australia investments |
---|---|
AbbVie Biotech Ventures | 1 |
Uniseed Ventures | 1 |
Alium Capital | 1 |
Bioplatforms Australia | 1 |
Accelerating Commercialisation - AusIndustry | 1 |
Possible Ventures | 1 |
Main Sequence Ventures | 1 |
Medical Research Commercialisation Fund (MRCF) | 1 |
Skalata | 1 |
OneVentures | 1 |
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, Italy
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro Breaks RecordWorld's Longest Wi-Fi HaLow Connection at 3 KilometersWatch Now Smarter, farther, better. Meet the latest Wi-Fi, HaLow, 802.11ah.
Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets.
It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.
Show more
Investment focus
- Software, Financial Services, FinTech
- Series A, Series B, Seed
- Australia, United States, Singapore
Portfolio highlights
- Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
- Academy Xi — Academy Xi is a future focused training company that provides short, practical and skill specific programs for individuals and teams to upgrade their capabilities in design and emerging technology. Our product mix is focused on emerging fields in Design and Tech and, in our classes, we aim to help individuals transform their careers. Ourteam training programs continue to attract large, progressive organisations who are looking to scale their design and tech capabilities. Using a structured, modular approach we customise our core programs to fit the unique needs of every company we engage with. We’re problem solvers and strive to embed purpose into what we do. Our vision is to truly transform the world through education and the community we’re building.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,187,380 freelance designers compete to create amazing designs for your business. Start Today!
Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more
Investment focus
- AgTech, Farming, Agriculture
- Pre-Seed
- Australia
Portfolio highlights
- Number 8 bio — Number 8 bio objective is to decarbonize agriculture while feeding the world's rising population. This can be accomplished by harnessing the power of trillions of carbon-hungry bacteria that feed on harmful greenhouse gases and turn them into profitable animal feeds.
A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda
Show more
Investment focus
- Software, Mining, Hardware
- Grant, Pre-Seed
- Australia
Portfolio highlights
- Neuromersiv — Neuromersiv empowers stroke and brain injury survivors with clinically designed virtual reality-based neurological rehabilitation solutions.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Pre-Seed, Series A
- Germany, Australia, United States
Portfolio highlights
- Heidi Health — Heidi Health is modernizing primary care with AI-powered technologies to improve care's quality and accessibility. its creators and engineers is to completely eradicate missed and sluggish diagnoses worldwide. They are committed to bridging the gap between the level of care that patients desire and the level of care that doctors can delivergiven their budget constraints. To create a platform where patients can quickly and easily get the treatment they require and to give every clinician the resources they need to deliver care that is secure, efficient,
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
- Cosmic Aerospace — Cosmic Aerospace is a pioneering aerospace technology company dedicated to advancing the boundaries of propulsion systems and enabling innovative solutions for space exploration. The company collaborates with leading space agencies, research institutions, and commercial partners to design, test, and implement these groundbreaking technologies.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Series A, Seed, Series B
- Australia, United States, Philippines
Portfolio highlights
- RIOS — We are helping enterprises automate their entire factories, warehouses or supply chain operations by deploying AI-powered end-to-end robotic workcells.
- Cauldron Ferm — Cauldron is sustainably delivering the precision fermented prototypes of today to the supermarket shelves of tomorrow.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more
Investment focus
- Software, Education, Apps
- Pre-Seed, Seed
- Australia, United States, United Kingdom
Portfolio highlights
- PropCode — PropCode is a online platform, that helps in researching for town planning queries. the rules can be complex, and make it easy to get the right answers.
- Tability — Automate the boring parts of OKRs to cut the waste and spend more time doing what really matters.
- Omni Biotech — Omni Biotech builds health and performance algorithms that work on all hardware platforms.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more
Investment focus
- Software, Health Care, Information Technology
- Series A, Debt Financing, Funding Round
- Australia, United States, Israel
Portfolio highlights
- BiVACOR — Replacing Hearts. Restoring Lives. HEART FAILURE Heart Failure (HF) is a devastating disease that affects more than 11 million people in the US and Europe, with an incidence of 1.1 million new cases per year. Furthermore, current growth rates predict a 25% increase in the incidence of HF by
- ImmVirX — ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.
- Employment Hero — Employment Hero is Australia's top cloud-based HR, payroll and benefits platform for employers & employees. FREE trial for...
Investors by industry
Health Care
Biotech
Community
Marketplace
FinTech
Impact
Proptech
Media (entertainment)
EdTech
Consumer
Climate
Energy
Hardware
Gaming
Artificial intelligence
Sustainability
Agriculture (agtech)
Venture Capital
Restaurants
Publishing
Beauty
Oil and Gas
Web3
Video Games
Food and Beverage
Clean Energy
Real Estate
Infrastructure
Big Data
Medical
Organic Food
Email
Wellness
Social Media
Music
Photography
Franchise
Celebrity
Android
Internet
Fashion
Legal
Google
Education
eSports
Construction
B2B
Local
Mobile
Renewable Energy
Enterprise Software
Sports
Payments
Social Network
Manufacturing
Digital Media
Financial Services
Facebook
Sporting Goods
Art
Social Impact
Finance
Retail
Recruiting
Platforms
Travel
Fitness
Mobile Advertising
Automotive
Cannabis
Biotechnology
Hospitality
CleanTech
Crowdfunding
Transportation
Mobile Apps
InsurTech
Wine And Spirits
Enterprise
Medical Device
Social
Film
LGBT
Life Science
Theatre
Non Profit
Software
SaaS
Cryptocurrency
Blockchain
Investors by country
Canada
United Kingdom
Ireland
Germany
South Korea
Australia
United States
India
New Zealand
Oceania
Armenia
China
Europe
Indonesia
LATAM
Middle East
Spain
Asia
Japan
South Africa
Qatar
Vietnam
Saudi Arabia
Singapore
Sri Lanka
Brazil
Africa
Czech Republic
Bahrain
Belize
Bermuda
Costa Rica
Belarus
Bulgaria
Kuwait
Denmark
Algeria
Georgia
Israel
Gibraltar
Cameroon
Chile
Jersey
Finland
Estonia
Kazakhstan
Faroe Islands
Greece
Ethiopia
Ghana
Nicaragua
Hungary
Croatia
Egypt
Belgium
Barbados
Ecuador
France
Hong Kong
Seychelles
Slovenia
Philippines
Russian Federation
Rwanda
Serbia
Uzbekistan
Togo
Italy
Taiwan
Ukraine
Sierra Leone
Turkey
Mali
Tunisia
Thailand
Tajikistan
Poland
Lithuania
Uganda
Zimbabwe
Tanzania
San Marino
Uruguay
Venezuela
Zambia
Senegal
Puerto Rico
Cambodia
Portugal
Liechtenstein
Sweden
El Salvador
Kenya
Nigeria
Liberia
Bahamas
Lebanon
Azerbaijan
Iraq
Iceland
Namibia
Mauritius
United Arab Emirates
Honduras
Morocco
Isle of Man
Bolivia
Luxembourg
Malaysia
Pakistan
Norway
Albania
Peru
Myanmar
Argentina
Cayman Islands
Bangladesh
Grenada
Jordan
Romania
Austria
Panama
Malta
Mexico
Colombia
Cyprus
Latvia
Oman
Switzerland
Guatemala
Marshall Islands
VC Funds in Australia by industry
Transportation
FinTech
Enterprise
Health Care
Consumer
Biotech
Climate
EdTech
Impact
Energy
SaaS
Proptech
Artificial intelligence
Marketplace
Community
Hardware
Restaurants
Crowdfunding
Mobile Apps
Venture Capital
Life Science
Real Estate
Oil and Gas
Finance
Cryptocurrency
Payments
Food and Beverage
InsurTech
Wine And Spirits
Video Games
Medical
Renewable Energy
Wellness
Medical Device
Email
Social Media
Internet
Digital Media
Social Network
Art
Manufacturing
Mobile
Music
Android
Blockchain
Legal
Software
Construction
eSports
Sports
CleanTech
Fitness
Hospitality
Travel
Automotive
Social
Biotechnology
Cannabis
Retail
Fashion
Web3
B2B
Beauty
Big Data
Publishing
Clean Energy
Education
Financial Services
Non Profit
Agriculture (agtech)
Recruiting
Gaming
Sustainability
Platforms
Social Impact
Media (entertainment)
Enterprise Software